foretinib

{
  "id": "MLC-T-ONC-003322",
  "term": "foretinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance being studied in the treatment of cancer. Foretinib blocks enzymes involved in the growth and spread of tumor cells. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called MET/VEGFR-2 inhibitor GSK1363089 and XL880.",
    "An orally bioavailable small molecule with potential antineoplastic activity. MET/VEGFR2 inhibitor GSK1363089 binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers. VEGFR2 is found on endothelial and hematopoietic cells and mediates the development of the vasculature and hematopoietic cells through VEGF signaling."
  ],
  "synonyms": [
    "MET/VEGFR-2 inhibitor GSK1363089",
    "XL880"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/foretinib/"
}